Want to see SE:ACARIX full AI Analyst Report?

Acarix AB (ACARIX) Price & Analysis

3 Followers

ACARIX Stock Chart & Stats

kr0.28

>-kr0.01(-3.04%)

At close: Mar 06 4:00 PM EST

kr0.28

>-kr0.01(-3.04%)

Day’s Range― - ―

52-Week Rangekr0.17 - kr0.34

Previous CloseN/A

Volume265.37K

Average Volume (3M)1.39M

Market Cap

kr227.76M

Enterprise Valuekr279.54M

Total Cash (Recent Filing)kr28.88M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.09

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding1,240,511,600

10 Day Avg. Volume1,031,418

30 Day Avg. Volume1,394,474

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)7.91

Price to Sales (P/S)41.02

P/FCF Ratio-6.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.1

Revenue Forecast (FY)kr14.00M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthRevenue growth shows that Acarix is expanding commercial activity and gaining adoption for its cardiovascular diagnostic offering. Although growth is from a small base, continued top-line expansion can improve operating leverage and provide a foundation for narrowing losses over the next several quarters.

Gross Margin ImprovementThe substantial gross-margin improvement indicates better unit economics and a stronger contribution from each unit of revenue. If maintained, this can support future operating leverage, reduce the revenue needed to cover fixed costs, and improve the economics of scaling the business.

Debt-Free Capital StructureA debt-free balance sheet limits refinancing and interest-rate risk while preserving flexibility for future financing and investment decisions. With assets largely supported by equity, Acarix avoids the fixed repayment burden that can intensify pressure during periods of operating loss.

Bears Say

Deep Operating LossesProfitability remains far below breakeven, with operating costs substantially exceeding the current revenue base. These losses indicate that revenue growth and improved gross margin have not yet translated into a sustainable earnings model, leaving the company exposed if progress toward scale slows.

Persistent Cash BurnNegative operating and free cash flow means the business is not yet funding its operations internally and continues to consume cash. Even though burn has improved versus 2025, the ongoing outflow increases reliance on external funding and can constrain investment capacity.

Equity ErosionMaterial equity erosion shows that continuing losses are consuming the capital base despite the absence of debt. Unless operating performance improves, this pattern can weaken financial resilience and increase the need for additional funding, with potential dilution risk for existing shareholders.

Acarix AB News

Is 7AC a Buy, Before Earnings?

Acarix AB (7AC) is scheduled to report 4th quarter earnings on 02/13/2025, before the market opens. Regarding Q4...

2y ago

7AC

ACARIX FAQ

What was Acarix AB’s price range in the past 12 months?

Acarix AB lowest stock price was kr0.17 and its highest was kr0.34 in the past 12 months.

What is Acarix AB’s market cap?

Acarix AB’s market cap is kr227.76M.

When is Acarix AB’s upcoming earnings report date?

Acarix AB’s upcoming earnings report date is Nov 05, 2026 which is in 6 days.

How were Acarix AB’s earnings last quarter?

Acarix AB released its earnings results on Aug 13, 2026. The company reported -kr0.008 earnings per share for the quarter.

Is Acarix AB overvalued?

According to Wall Street analysts Acarix AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Acarix AB pay dividends?

Acarix AB does not currently pay dividends.

What is Acarix AB’s EPS estimate?

Acarix AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Acarix AB have?

Acarix AB has 1,240,511,600 shares outstanding.

What happened to Acarix AB’s price movement after its last earnings report?

Acarix AB reported an EPS of -kr0.008 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Acarix AB?

Currently, no hedge funds are holding shares in SE:ACARIX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Acarix AB

Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADScor System, an exceptionally sensitive, non-invasive analytical device designed for the detection of coronary artery disease. Founded in 2009, Acarix AB (publ) maintains its headquarters in Malmö, Sweden.